Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-07T14:30:34.190Z Has data issue: false hasContentIssue false
  • English
  • Français

X-ray powder diffraction data for 5, 6-dihydro-3-(4-morpholinyl)-1-[4-(2-oxo-1-piperidinyl)phenyl]-2(1H)-pyridinone, C20H25N3O3

Published online by Cambridge University Press:  13 July 2016

Qing Wang ,
Xia Zeng ,
Shan Shan Li ,
Xiao Li Ma  and
Hui Li
Qing Wang
Affiliation:
College of Chemical Engineering, Sichuan University, Chengdu 610065, China
Xia Zeng
Affiliation:
College of Chemical Engineering, Sichuan University, Chengdu 610065, China
Shan Shan Li
Affiliation:
College of Chemical Engineering, Sichuan University, Chengdu 610065, China
Xiao Li Ma
Affiliation:
College of Chemical Engineering, Sichuan University, Chengdu 610065, China
Hui Li*
Affiliation:
College of Chemical Engineering, Sichuan University, Chengdu 610065, China
*
a)Author to whom correspondence should be addressed. Electronic mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

X-ray powder diffraction data for 5,6-dihydro-3-(4-morpholinyl)-1-[4-(2-oxo-1-piperidinyl)phenyl]-2(1H)-pyridinone, C20H25N3O3, are reported [a = 5.989(2), b = 6.669(3), c = 24.605(5)Å, α = 84.466(7)°, β = 89.859(6)°, γ = 69.074(4)°, unit-cell volume V = 913.11 Å3, Z = 2, and space group P−1]. No detectable impurities were observed.

Keywords

pharmaceutical intermediateanticoagulantapixabansingle crystal
Type
New Diffraction Data
Information
Powder Diffraction , Volume 31 , Issue 4 , December 2016 , pp. 288 - 291
Check for updates
Copyright
Copyright © International Centre for Diffraction Data 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Deeks, E. D. (2012). “Apixaban,” Drugs 72(9), 1271–1291.CrossRefGoogle ScholarPubMed
Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K., and Puschmann, H. (2009). “OLEX2: a complete structure solution, refinement and analysis program,” J. Appl. Crystallogr. 42, 339–341.CrossRefGoogle Scholar
Jiang, J. and Ji, Y. (2013) “Alternate synthesis of apixaban (BMS-562247), an inhibitor of blood coagulation factor Xa”, Synth. Commun. 43(1), 72–79.Google Scholar
Neumann, M. A. (2003). “X-cell: a novel indexing algorithm for routine tasks and difficult cases,” J. Appl. Crystallogr. 36, 356–365.CrossRefGoogle Scholar
Pawley, G. S. (1981). “Unit-cell refinement from powder diffraction scans,” J. Appl. Crystallogr. 14(6), 357–361.CrossRefGoogle Scholar
Sheldrick, G. M. (2008). “Foundations of crystallography,” Acta Crystallogr. A 64, 112–122.Google Scholar
Wang, Y., Xiang, Y. Z., Cen, G. D., Zhang, J. B., Huang, L., Zhou, N., Liu, J., and Qiao, H. (2015). “Pyrazole derivative and medical application,” WO Pat., 2015070809.Google Scholar
Watson, J., Whiteside, G., and Perry, C. (2011). “Apixaban,” Drugs 71, 2079–2089.Google Scholar
Supplementary material: File

Wang supplementary material

Wang supplementary material 1

Download Wang supplementary material(File)
File 113.9 KB
Supplementary material: File

Wang supplementary material

Wang supplementary material 2

Download Wang supplementary material(File)
File 21.2 KB